Shares of Antero Midstream Partners LP (NYSE: AM), which owns, operates and develops midstream energy assets, have pulled back adequately enough to render the valuation attractive, according to Stifel.
Stifel's Timothy Howard upgraded Antero from Hold to Buy and assigned a $35 price target.
Antero Midstream Partners units have lost about 10 percent since Stifel's Aug. 2 downgrade versus a less-than-1-percent gain in the Alerian Index, Howard said in the upgrade note. (See the analyst's track record here.)
The consolidated Antero Midstream — assuming general partner Antero Midstream GP LP (NYSE: AMGP) buys it at no premium to Monday's close — is trading at 11.6 times Stifel's 2019 adjusted EBITDA estimate, the analyst said.
This compares to a 12.6 times multiple at the time of Stifel's downgrade, Howard said.
"While uncertainty remains around Antero's strategic review outcome, we believe the pullback in AM and the consolidated entity's valuation creates a more compelling entry point," the analyst said. "Since Antero Resources Corp (NYSE: AR) activism drove this strategic review due to conflicts of interest, we believe investors are well served by aligning themselves with AR shareholders through AM units."
Citing an updated model for 10-Q segment level data, Stifel moderated its 2018 estimates for Antero Midstream Partners and said it expects adjusted EBITDA of $707 million and discounted cash flow of $577 million compared to its previous estimates of $710 million and $582 million, respectively. The firm slightly increased 2019 estimates.
Antero Midstream Partners units have gained 8.7 percent year-to-date.
Natural Gas: Morgan Stanley's 2018 Outlook
Making The Natural Gas Trade Great Again
Latest Ratings for AM
|Aug 2018||Stifel Nicolaus||Upgrades||Hold||Buy|
|Aug 2018||JP Morgan||Maintains||Neutral||Neutral|
|Aug 2018||Wells Fargo||Maintains||Outperform||Outperform|
View More Analyst Ratings for AM
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent
- Memory Exposure Drives BofA Downgrade Of Lam Research, Applied Materials; Analyst Says KLA-Tencor A Defensive Pick
- Xilinx Notches Baird Upgrade As 5G Demand Accelerates
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.